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Background: Nesiritide improves symptoms and hemodynamics in patients with left ventricular (LV) failure (LVF). We evaluated for the first time 
nesiritide’s effect on renal function in patients with acute decompensated heart failure (ADHF) and normal LV function and we compared this effect 
in patients with right ventricular (RV) failure versus patients with no RV failure. 
Methods: We reviewed data of 657 patients admitted to AECOM with ADHF and normal LV systolic function. 140 patients had isolated RV failure 
secondary to pulmonary hypertension and 517 patients had normal right ventricular function. In the RVF group, 70 were treated with IV nesiritide 
while the remaining 70 patients received only IV furosemide and served as controls. In the non RVF group, 258 received nesiritide and 259 served as 
controls. Serum creatinine and GFR levels at baseline, 3 days, time of discharge and one month post-treatment were assessed.
Results: The results for RVF and non RVF groups (nesiritide and controls) are shown in fig1. There was a significant difference between RVF and non 
RVF nesiritide group in the mean change of GFR at 1 month (-8.22± 8.98 vs.3.55 ± 19.88, p<0.001).. Similar results were noted for all groups when 
we used creatinine data. .
Conclusions:  Caution should be exercised when using nesiritide in patients with RV failure and renal failure. Interestingly, patients with 
normal RV function seem to recover their renal function at 1 month after nesiritide infusion despite an initial significant deterioration. 
